Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection | Zendy

Ka Lai Yee | Zendy; Huub Jan Kleijn | Zendy; Thomas Kerbusch | Zendy; Randolph P. Matthews | Zendy; Marcus Dörr | Zendy; Kevin W. Garey | Zendy; Rebecca E. Wrishko | Zendy

Open Access

Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection

Author(s) -

Ka Lai Yee,

Huub Jan Kleijn,

Thomas Kerbusch,

Randolph P. Matthews,

Marcus Dörr,

Kevin W. Garey,

Rebecca E. Wrishko

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01971-18

Subject(s) - clostridium difficile , medicine , pharmacodynamics , clostridioides , pharmacokinetics , population , clostridium infections , clostridium , microbiology and biotechnology , antibiotics , biology , bacteria , genetics , environmental health

The fully human monoclonal antibody bezlotoxumab is indicated for preventing the recurrence ofClostridioides difficile (formerlyClostridium difficile ) infection (CDI) in adults who receive antibacterial treatment for CDI and who are at high risk for a CDI recurrence. The efficacy and safety of 10-mg/kg of body weight bezlotoxumab were demonstrated in two phase 3 trials: the MODIFY I (ClinicalTrials.gov registration number NCT01241552) and MODIFY II (ClinicalTrials.gov registration number NCT01513239) trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research